Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma
The ubiquitin-proteasome pathway has been identified as a potential molecular target for cancer therapy. In this study, we investigated the effect of the proteasome inhibitor bortezomib on anaplastic thyroid carcinoma (ATC) characterized by complete refractoriness to multimodal therapeutic approache...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 10, 2012
|
| In: |
Journal of nuclear medicine
Year: 2012, Volume: 53, Issue: 11, Pages: 1764-1771 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.111.101295 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.2967/jnumed.111.101295
|
| Author Notes: | Annette Altmann, Annette Markert, Vasileios Askoxylakis, Tilman Schöning, Ralf Jesenofsky, Michael Eisenhut and Uwe Haberkorn |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1575025086 | ||
| 003 | DE-627 | ||
| 005 | 20230427042900.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180514s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.111.101295 |2 doi | |
| 035 | |a (DE-627)1575025086 | ||
| 035 | |a (DE-576)505025086 | ||
| 035 | |a (DE-599)BSZ505025086 | ||
| 035 | |a (OCoLC)1341009460 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Altmann, Annette |e VerfasserIn |0 (DE-588)1032267984 |0 (DE-627)738189111 |0 (DE-576)379930099 |4 aut | |
| 245 | 1 | 0 | |a Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma |c Annette Altmann, Annette Markert, Vasileios Askoxylakis, Tilman Schöning, Ralf Jesenofsky, Michael Eisenhut and Uwe Haberkorn |
| 264 | 1 | |c October 10, 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.05.2018 | ||
| 520 | |a The ubiquitin-proteasome pathway has been identified as a potential molecular target for cancer therapy. In this study, we investigated the effect of the proteasome inhibitor bortezomib on anaplastic thyroid carcinoma (ATC) characterized by complete refractoriness to multimodal therapeutic approaches. METHODS: The ATC cell lines C643 and SW1736 were treated with bortezomib (1 nM to 1 μM) for 12-72 h. Thereafter, growth inhibition was analyzed by thymidine uptake experiments and determination of the viable cell number. Apoptosis was measured and a cell cycle analysis was done. Using gene chip analysis and the real-time quantitative PCR system, we measured transcriptional changes. The activity of the nuclear factor (NF)-κB and p53 signal transduction pathways was monitored using the reporter constructs pNF-κB-TA-Luc and pp53-TA-Luc in the luciferase activity assay. Uptake measurements using (3)H-FDG, (14)C-aminoisobutyric acid, and Na(125)iodide were performed to investigate metabolic changes and iodide symporter activity in vitro. Moreover, the (18)F-FDG uptake was evaluated in ATC tumor-bearing nude mice 1 or 2 d after treatment with bortezomib. RESULTS: Bortezomib induced growth inhibition, apoptosis, and G(2)-M cell cycle arrest associated with upregulation of p21(CIP1/WAF1) expression in SW1736 and C643 cells. Moreover, the glucose metabolism and aminoisobutyric acid uptake significantly decreased in vitro in both of the ATC cell lines in vivo only in SW1736 tumors at 2 d after the bortezomib treatment. The transcriptional profile in bortezomib-treated SW1736 and C643 cells revealed increased expression of genes involved in stress response, apoptosis, regulation of the cell cycle, and differentiation. Using real-time quantitative PCR for the quantification of gene expression, we additionally noticed upregulation of the tumor necrosis factor-related apoptosis-inducing ligand and the thyroid-specific transcription factors Pax8 and TTF-1, leading to expression of the thyroid-specific target genes thyroglobulin, sodium iodide symporter, thyroperoxidase, and thyroid-stimulating hormone receptor and to a moderate accumulation of iodide in ATC cells. CONCLUSION: On the basis of our data, bortezomib represents a promising antineoplastic agent for the treatment of ATC. To improve the clinical outcome, further investigation into the potential of bortezomib therapy of thyroid cancer is clearly warranted. | ||
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Antineoplastic Agents | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Boronic Acids | |
| 650 | 4 | |a Bortezomib | |
| 650 | 4 | |a Cell Cycle Checkpoints | |
| 650 | 4 | |a Cell Line, Tumor | |
| 650 | 4 | |a Cell Proliferation | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Mice | |
| 650 | 4 | |a Mice, Inbred BALB C | |
| 650 | 4 | |a Organ Specificity | |
| 650 | 4 | |a Proteasome Endopeptidase Complex | |
| 650 | 4 | |a Proteasome Inhibitors | |
| 650 | 4 | |a Pyrazines | |
| 650 | 4 | |a Thyroid Carcinoma, Anaplastic | |
| 650 | 4 | |a Thyroid Neoplasms | |
| 650 | 4 | |a Up-Regulation | |
| 650 | 4 | |a Xenograft Model Antitumor Assays | |
| 700 | 1 | |a Askoxylakis, Vasileios |d 1978- |e VerfasserIn |0 (DE-588)133302261 |0 (DE-627)69132753X |0 (DE-576)276112148 |4 aut | |
| 700 | 1 | |a Schöning, Tilman |d 1972- |e VerfasserIn |0 (DE-588)140330836 |0 (DE-627)617702489 |0 (DE-576)316456705 |4 aut | |
| 700 | 1 | |a Jesenofsky, Ralf |d 1960- |e VerfasserIn |0 (DE-588)1029758042 |0 (DE-627)734019238 |0 (DE-576)377606448 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine |d New York, NY : Soc., 1964 |g 53(2012), 11, Seite 1764-1771 |h Online-Ressource |w (DE-627)325793603 |w (DE-600)2040222-3 |w (DE-576)09475277X |x 2159-662X |7 nnas |a Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma |
| 773 | 1 | 8 | |g volume:53 |g year:2012 |g number:11 |g pages:1764-1771 |g extent:8 |a Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma |d 2012 |w (DE-627)1449903738 |w (DE-576)379903733 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2967/jnumed.111.101295 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180514 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 7 |y j | ||
| 998 | |g 1029758042 |a Jesenofsky, Ralf |m 1029758042:Jesenofsky, Ralf |d 60000 |d 61100 |e 60000PJ1029758042 |e 61100PJ1029758042 |k 0/60000/ |k 1/60000/61100/ |p 5 | ||
| 998 | |g 140330836 |a Schöning, Tilman |m 140330836:Schöning, Tilman |d 910000 |e 910000PS140330836 |k 0/910000/ |p 4 | ||
| 998 | |g 133302261 |a Askoxylakis, Vasileios |m 133302261:Askoxylakis, Vasileios |d 910000 |d 911400 |e 910000PA133302261 |e 911400PA133302261 |k 0/910000/ |k 1/910000/911400/ |p 3 | ||
| 998 | |g 1032267984 |a Altmann, Annette |m 1032267984:Altmann, Annette |d 910000 |d 911400 |e 910000PA1032267984 |e 911400PA1032267984 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1575025086 |e 3009269471 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"physDesc":[{"extent":"8 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"October 10, 2012"}],"recId":"1575025086","relHost":[{"note":["Gesehen am 13.12.2021"],"name":{"displayForm":["Society of Nuclear Medicine"]},"recId":"325793603","type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"New York, NY","dateIssuedKey":"1964","publisher":"Soc.","dateIssuedDisp":"1964-"}],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"Society of Nuclear Medicine","role":"isb"}],"disp":"Antitumor effects of proteasome inhibition in anaplastic thyroid carcinomaJournal of nuclear medicine","title":[{"title":"Journal of nuclear medicine","title_sort":"Journal of nuclear medicine","subtitle":"JNM"}],"titleAlt":[{"title":"JNM"}],"id":{"issn":["2159-662X","1535-5667"],"eki":["325793603"],"zdb":["2040222-3"]},"pubHistory":["Nachgewiesen 5.1964 -"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"11","pages":"1764-1771","text":"53(2012), 11, Seite 1764-1771","year":"2012","extent":"8","volume":"53"},"language":["eng"]}],"id":{"eki":["1575025086"],"doi":["10.2967/jnumed.111.101295"]},"person":[{"family":"Altmann","role":"aut","display":"Altmann, Annette","roleDisplay":"VerfasserIn","given":"Annette"},{"family":"Askoxylakis","role":"aut","display":"Askoxylakis, Vasileios","roleDisplay":"VerfasserIn","given":"Vasileios"},{"role":"aut","family":"Schöning","given":"Tilman","display":"Schöning, Tilman","roleDisplay":"VerfasserIn"},{"role":"aut","family":"Jesenofsky","display":"Jesenofsky, Ralf","roleDisplay":"VerfasserIn","given":"Ralf"},{"roleDisplay":"VerfasserIn","display":"Haberkorn, Uwe","given":"Uwe","role":"aut","family":"Haberkorn"}],"name":{"displayForm":["Annette Altmann, Annette Markert, Vasileios Askoxylakis, Tilman Schöning, Ralf Jesenofsky, Michael Eisenhut and Uwe Haberkorn"]},"note":["Gesehen am 14.05.2018"],"title":[{"title_sort":"Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma","title":"Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma"}]} | ||
| SRT | |a ALTMANNANNANTITUMORE1020 | ||